George Hillman - Viracta Therapeutics CoFounder
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Insider
George Hillman is CoFounder of Viracta Therapeutics
| Phone | 858 400 8470 |
| Web | https://www.viracta.com |
Viracta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Viracta Therapeutics currently holds 25.56 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Viracta Therapeutics has a current ratio of 11.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Viracta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Viracta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viracta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viracta to invest in growth at high rates of return. When we think about Viracta Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Shinyu MD | IGM Biosciences | 55 | |
| Suzette Tauber | IGM Biosciences | 61 | |
| Deepak MD | Tenaya Therapeutics | 59 | |
| MD FACP | Rallybio Corp | 74 | |
| David MBA | Vincerx Pharma | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| MA MS | Inozyme Pharma | N/A | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Franco Valle | Biomea Fusion | 43 | |
| Christian Heinis | Bicycle Therapeutics | N/A | |
| John MD | Vincerx Pharma | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| FACR MD | Cabaletta Bio | 59 | |
| AFPM MD | Trevi Therapeutics | 57 | |
| Eric Olson | Tenaya Therapeutics | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Christine Granfield | Leap Therapeutics | 57 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
Management Performance
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 |
Viracta Therapeutics Leadership Team
Elected by the shareholders, the Viracta Therapeutics' board of directors comprises two types of representatives: Viracta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viracta. The board's role is to monitor Viracta Therapeutics' management team and ensure that shareholders' interests are well served. Viracta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viracta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel CPA, COO, CFO | ||
| Cheryl Madsen, Senior Affairs | ||
| Daniel Chevallard, COO CFO | ||
| Thalia MD, CoFounder | ||
| Patric MBA, Senior Strategy | ||
| Ronald MD, CoFounder Consultant | ||
| George Hillman, CoFounder | ||
| Robert Williams, CoFounder | ||
| Robert McRae, Vice Alliances | ||
| Ayman ElGuindy, Chief Officer | ||
| Mark Rothera, President CEO | ||
| Stewart Brown, Senior Counsel | ||
| Susan MD, Scientific Consultant | ||
| Michael Faerm, Chief Officer | ||
| Lisa Rojkjaer, Chief Officer | ||
| Biljana PharmD, Senior Development |
Viracta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viracta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (3.02 M) | ||||
| Shares Outstanding | 39.74 M | ||||
| Shares Owned By Insiders | 2.98 % | ||||
| Shares Owned By Institutions | 39.80 % | ||||
| Number Of Shares Shorted | 246.03 K | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |